Friends - It's time for some very conservative val
Post# of 405
Posted On: 09/14/2016 6:51:12 PM
Friends - It's time for some very conservative valuations of this company:
- INNV was trading at 8 cents with approx. 52M o/s and $1M in revenue
- Now we are on track for $5M in revs for 2016 not counting what will be 4 months of recalmax sales. We already are cash flow positive. o/s has doubled, though
5x8 = 40 /2 = 20 cents (not even counting recalmax and little premium for Fluticare approval factored in)
BUT WAIT:
Fluticare approval likely brings in 13M from US sales and another 6M from Int'l within the first year.
PLUS guidance for 2017 is 15M without Fluticare. This figure is from existing products and projected sales from launch of 2 new upcoming products (not Fluticare) SO:
IF/WHEN 2017 ends and we do get 19M + the 15M, with maybe only 130M o/s shares at that time then:
8 cents per $1M rev x 34 / 2.5 = $1.09 (and I doubt o/s would even be as high as 130M then)
Conclusion: If Qtr over Qtr Financials are lining up as projected or slightly exceeding expectations AND Fluticare is approved by end of say October, then 1.09 is a given and this is with a ZERO MULTIPLE. Let me state that again....a ZERO MULTIPLE. Also assumes no more acquisitions and NO Buyout Offers. Have to figure in a premium for that. Keep in mind that stock market is 6-8 months forward looking.
* I urge everyone to take 45 seconds and send out a tweet/post to target audiences ! (Sexual dysfunction sites / Diabetes / Low-T / Dementia / Alzheimers / Vision) You help them with product solutions as you help out your company and your wallet !!! THINK
- INNV was trading at 8 cents with approx. 52M o/s and $1M in revenue
- Now we are on track for $5M in revs for 2016 not counting what will be 4 months of recalmax sales. We already are cash flow positive. o/s has doubled, though
5x8 = 40 /2 = 20 cents (not even counting recalmax and little premium for Fluticare approval factored in)
BUT WAIT:
Fluticare approval likely brings in 13M from US sales and another 6M from Int'l within the first year.
PLUS guidance for 2017 is 15M without Fluticare. This figure is from existing products and projected sales from launch of 2 new upcoming products (not Fluticare) SO:
IF/WHEN 2017 ends and we do get 19M + the 15M, with maybe only 130M o/s shares at that time then:
8 cents per $1M rev x 34 / 2.5 = $1.09 (and I doubt o/s would even be as high as 130M then)
Conclusion: If Qtr over Qtr Financials are lining up as projected or slightly exceeding expectations AND Fluticare is approved by end of say October, then 1.09 is a given and this is with a ZERO MULTIPLE. Let me state that again....a ZERO MULTIPLE. Also assumes no more acquisitions and NO Buyout Offers. Have to figure in a premium for that. Keep in mind that stock market is 6-8 months forward looking.
* I urge everyone to take 45 seconds and send out a tweet/post to target audiences ! (Sexual dysfunction sites / Diabetes / Low-T / Dementia / Alzheimers / Vision) You help them with product solutions as you help out your company and your wallet !!! THINK
(1)
(0)Innovus Pharmaceuticals Inc. (INNV) Stock Research Links
Scroll down for more posts ▼